Surgepays is trading at $0.12, down 5.85%, with no new company-specific announcement identified to explain the October 13 decline.

  • Recent coverage points to a Nasdaq extension granted in September, rather than a new event today. An SEC filing says Surgepays has until March 22, 2027, to regain the $1.00 bid-price requirement and may use a reverse split if necessary.
  • Broader indexes were only modestly lower, so the supplied market context does not establish a clear explanation for the drop.